Pfizer (PFE) Shares Bought by D.A. Davidson & CO.


D.A. Davidson & CO. grew its stake in Pfizer (NYSE:PFE) by 3.7% during the fourth quarter, HoldingsChannel reports. The firm owned 402,659 shares of the biopharmaceutical company’s stock after buying an additional 14,417 shares during the quarter. D.A. Davidson & CO.’s holdings in Pfizer were worth $14,584,000 at the end of the most recent reporting period.


Several other institutional investors and hedge funds also recently bought and sold shares of PFE. Investment Centers of America Inc. raised its holdings in Pfizer by 2.3% in the 3rd quarter. Investment Centers of America Inc. now owns 195,611 shares of the biopharmaceutical company’s stock valued at $6,990,000 after buying an additional 4,472 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH raised its holdings in Pfizer by 437.9% in the 3rd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 773,073 shares of the biopharmaceutical company’s stock valued at $27,607,000 after buying an additional 629,361 shares during the last quarter. SG Americas Securities LLC raised its holdings in Pfizer by 3,116.6% in the 4th quarter. SG Americas Securities LLC now owns 1,186,121 shares of the biopharmaceutical company’s stock valued at $42,961,000 after buying an additional 1,149,246 shares during the last quarter. Oldfield Partners LLP raised its holdings in Pfizer by 33.1% in the 4th quarter. Oldfield Partners LLP now owns 109,850 shares of the biopharmaceutical company’s stock valued at $3,979,000 after buying an additional 27,300 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund raised its holdings in Pfizer by 1.2% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 1,652,936 shares of the biopharmaceutical company’s stock valued at $59,010,000 after buying an additional 19,989 shares during the last quarter. Institutional investors own 71.57% of the company’s stock.


Get Pfizer alerts:

In related news, CEO Ian C. Read sold 132,312 shares of Pfizer stock in a transaction on Tuesday, May 1st. The shares were sold at an average price of $36.01, for a total value of $4,764,555.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director W Don Cornwell sold 1,758 shares of Pfizer stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total transaction of $64,676.82. Following the completion of the sale, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $36,790. The disclosure for this sale can be found here. Insiders sold a total of 380,349 shares of company stock valued at $13,829,340 in the last quarter. 0.06% of the stock is currently owned by company insiders.


NYSE:PFE opened at $34.93 on Tuesday. The firm has a market capitalization of $207.40 billion, a PE ratio of 13.18, a P/E/G ratio of 1.73 and a beta of 0.89. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.35 and a quick ratio of 1.10. Pfizer has a twelve month low of $31.67 and a twelve month high of $39.43.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.03. The company had revenue of $12.91 billion during the quarter, compared to analyst estimates of $13.14 billion. Pfizer had a net margin of 41.29% and a return on equity of 25.96%. Pfizer’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.69 EPS. analysts forecast that Pfizer will post 2.95 EPS for the current fiscal year.


The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, May 11th will be paid a $0.34 dividend. The ex-dividend date is Thursday, May 10th. This represents a $1.36 annualized dividend and a dividend yield of 3.89%. Pfizer’s dividend payout ratio is currently 51.32%.

A number of research analysts recently issued reports on the stock. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, January 30th. SunTrust Banks restated a “hold” rating and set a $40.00 price target (up previously from $33.00) on shares of Pfizer in a report on Monday, January 29th. Morgan Stanley raised their price target on shares of Pfizer from $41.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. UBS set a $42.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, January 31st. Finally, Societe Generale set a $40.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Wednesday, January 31st. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $39.57.


Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Leave a Reply

Your email address will not be published. Required fields are marked *